Genen­tech dis­solves can­cer im­munol­o­gy group, and re­search ex­ec­u­tive Ira Mell­man will leave com­pa­ny

9 months ago
People
Pharma

Biden ad­min­is­tra­tion touts big drug sav­ings from IRA, but con­fi­den­tial dis­counts make it im­pos­si­ble to ver­i­fy their ...

9 months ago
Pharma

Up­dat­ed: Lykos cut­ting most of staff less than a week af­ter FDA re­jec­tion

9 months ago
People
FDA+

Bavar­i­an Nordic re­turns to the spot­light as mpox out­break reach­es emer­gency state

9 months ago
Pharma
Manufacturing

Lyra paus­es work on si­nusi­tis drug; Pathos AI li­cens­es a new as­set

9 months ago
News Briefing

Mer­ck signs MoU with In­di­an CD­MO; Scor­pius de­lays pub­lic of­fer­ing

9 months ago
Manufacturing

Up­dat­ed: NIH says SIGA’s an­tivi­ral didn’t im­prove res­o­lu­tion in mpox le­sions in the DRC

9 months ago
R&D

Up­dat­ed: Fed­er­al gov­ern­ment re­veals ne­go­ti­at­ed prices un­der In­fla­tion Re­duc­tion Act

9 months ago
Pharma
FDA+

In a re­al­i­ty check for the field, AI un­der­whelms in Leash Bio's bind­ing con­test: 'No one did well'

9 months ago
AI

Biden ad­min­is­tra­tion says IRA ne­go­ti­a­tions will re­sult in $6B in 2026 Medicare sav­ings

9 months ago
FDA+
Law

Zealand joins next-gen club aim­ing to ‘ac­cel­er­ate’ obe­si­ty drug de­vel­op­ment

9 months ago
R&D

In­cyte gets an­oth­er graft-ver­sus-host dis­ease drug ap­proval, this time with part­ner Syn­dax

9 months ago
R&D
Pharma

FDA warn­ing let­ter tar­gets doc­tor who worked on a Take­da Phase 3 study

9 months ago
FDA+

Blue­bird's slow sick­le cell launch forces re­work of loan, putting cash run­way at risk

9 months ago
Pharma
Cell/Gene Tx

Ar­row­head lays out ear­ly-stage obe­si­ty strat­e­gy, in­clud­ing new tar­get on fat-stor­ing cells

9 months ago
R&D
Pharma

In­vest­ment in ear­ly-stage health tech star­tups climbed in the first half of 2024, re­port shows

9 months ago
Financing
Startups

Gilead wins FDA ac­cel­er­at­ed ap­proval of se­ladel­par af­ter ac­quir­ing it in $4.3B deal

9 months ago
Pharma
FDA+

Sanofi backs Anap­tys­Bio’s $100M of­fer­ing, help­ing cat­a­pult the biotech’s stock

9 months ago
Financing
Deals

Ver­ri­ca’s stock dips de­spite Phase 2 skin can­cer drug clear­ing more than 50% of le­sions

9 months ago
R&D

Evotec to cut 400 work­ers and close sites, cit­ing ‘no new sig­nals of re­cov­ery’ this year

9 months ago
Pharma
Manufacturing

An­oth­er of­fer­ing for Avid­i­ty; Galera shuts down

9 months ago
News Briefing

Avenge Bio, a cell ther­a­py biotech from Rice, is closed

9 months ago
Cell/Gene Tx

Metageno­mi tin­kers with pipeline af­ter CSO de­par­ture, says Affi­ni-T and Io­n­is pacts are pro­gress­ing

9 months ago
Startups
R&D

As­traZeneca's Imfinzi, Lyn­parza com­bo ap­proved in EU for cer­tain en­dome­tri­al can­cer pa­tients

9 months ago
Pharma
First page Previous page 116117118119120121122 Next page Last page
A service from the Financial Times